Literature DB >> 23739916

HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis.

Malte Mohme1, Christian Hotz, Stefan Stevanovic, Thomas Binder, Jar-How Lee, Michal Okoniewski, Thomas Eiermann, Mireia Sospedra, Hans-Georg Rammensee, Roland Martin.   

Abstract

The HLA-DR15 haplotype confers the largest part of the genetic risk to develop multiple sclerosis, a prototypic CD4+ T cell-mediated autoimmune disease. The mechanisms how certain HLA-class II molecules functionally contribute to autoimmune diseases are still poorly understood, but probably involve shaping an autoimmune-prone T cell repertoire during central tolerance in the thymus and subsequently maintaining or even expanding it in the peripheral immune system. Self-peptides that are presented by disease-associated HLA-class II molecules most likely play important roles during both processes. Here, we examined the functional involvement of the HLA-DR15 haplotype in autologous proliferation in multiple sclerosis and the contribution of HLA-DR15 haplotype-derived self-peptides in an in vitro system. We observe increased autologous T cell proliferation in patients with multiple sclerosis in relation to the multiple sclerosis risk-associated HLA-DR15 haplotype. Assuming that the spectrum of self-peptides that is presented by the two HLA-DR15 allelic products is important for sustaining autologous proliferation we performed peptide elution and identification experiments from the multiple sclerosis-associated DR15 molecules and a systematic analysis of a DR15 haplotype-derived self-peptide library. We identify HLA-derived self-peptides as potential mediators of altered autologous proliferation. Our data provide novel insights about perturbed T cell repertoire dynamics and the functional involvement of the major genetic risk factor, the HLA-DR15 haplotype, in multiple sclerosis.

Entities:  

Keywords:  HLA-DR15; autologous T cell proliferation; homeostatic proliferation; multiple sclerosis; self-peptides

Mesh:

Substances:

Year:  2013        PMID: 23739916     DOI: 10.1093/brain/awt108

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  18 in total

1.  Immune-cell crosstalk in multiple sclerosis.

Authors:  Richard M Ransohoff
Journal:  Nature       Date:  2018-11       Impact factor: 49.962

2.  PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs.

Authors:  Anna Mestre-Ferrer; Erika Scholz; Jepi Humet-Alsius; Iñaki Alvarez
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

3.  Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells.

Authors:  Joshua D Ooi; Jan Petersen; Yu H Tan; Megan Huynh; Zoe J Willett; Sri H Ramarathinam; Peter J Eggenhuizen; Khai L Loh; Katherine A Watson; Poh Y Gan; Maliha A Alikhan; Nadine L Dudek; Andreas Handel; Billy G Hudson; Lars Fugger; David A Power; Stephen G Holt; P Toby Coates; Jon W Gregersen; Anthony W Purcell; Stephen R Holdsworth; Nicole L La Gruta; Hugh H Reid; Jamie Rossjohn; A Richard Kitching
Journal:  Nature       Date:  2017-05-03       Impact factor: 49.962

Review 4.  Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.

Authors:  Luc Van Kaer; Joshua L Postoak; Chuan Wang; Guan Yang; Lan Wu
Journal:  Cell Mol Immunol       Date:  2019-03-15       Impact factor: 11.530

5.  A short HLA-DRA isoform binds the HLA-DR2 heterodimer on the outer domain of the peptide-binding site.

Authors:  Hengameh Shams; Jill A Hollenbach; Atsuko Matsunaga; Mohammad R K Mofrad; Jorge R Oksenberg; Alessandro Didonna
Journal:  Arch Biochem Biophys       Date:  2022-02-24       Impact factor: 4.013

6.  A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data?

Authors:  Kerrie Vaughan; Bjoern Peters; Kevin C O'Connor; Roland Martin; Alessandro Sette
Journal:  J Neuroimmunol       Date:  2013-12-12       Impact factor: 3.478

Review 7.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

8.  Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires.

Authors:  Erika Margaret Scholz; Miguel Marcilla; Xavier Daura; David Arribas-Layton; Eddie A James; Iñaki Alvarez
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

9.  A splice acceptor variant in HLA-DRA affects the conformation and cellular localization of the class II DR alpha-chain.

Authors:  Alessandro Didonna; Vincent Damotte; Hengameh Shams; Atsuko Matsunaga; Stacy J Caillier; Ravi Dandekar; Maneesh K Misra; Mohammad R K Mofrad; Jorge R Oksenberg; Jill A Hollenbach
Journal:  Immunology       Date:  2020-10-19       Impact factor: 7.397

10.  The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response.

Authors:  Pierre Abramowski; Benjamin Otto; Roland Martin
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.